The new coronavirus currently lacks vaccine and proven therapeutics. Credit: Arek Socha from Pixabay.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Canada-based ImmunoPrecise Antibodies has initiated a research programme focused on the development of vaccine and therapeutic antibodies against the coronavirus, SARS-CoV-2.

The company is working on the design and generation of target antigens for the virus.

These antigens are intended to help identify prophylactic and therapeutic compounds using the company’s discovery platforms, including B Cell Select and DeepDisplay.

For the project, the company will also leverage its subsidiary Talem Therapeutic’s access to the OmniAb transgenic animal platform to produce human antibodies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ImmunoPrecise Antibodies president and CEO Dr Jennifer Bath said: “We believe that ImmunoPrecise will make an impressive contribution to the global fight against SARS-CoV-2.

“With the aid of iterative advancements rapidly compiling from across the globe, including data such as the February 19th release of the prefusion form of the new coronavirus spike glycoprotein, research teams are advancing the collective effort toward the development of efficacious vaccines, therapeutic antibodies, and diagnostics.

“We grow more determined each day about contributing to this endeavour, as we monitor the rapid, global spread of SARS-CoV-2.”

Talem Therapeutic scientific committee chairwoman Dr Ilse Roodink has been appointed as the global leader for the coronavirus project.

See all Coronavirus vaccines and drugs in the pipeline